SARS-CoV2感染对系统性红斑狼疮患者疾病复发的影响:一项病例对照研究
回顾性纳入91例符合ACR/SLICC标准且确诊COVID-19的SLE患者,按年龄、性别和感染时间2:1随机匹配182例无SARS-CoV2感染的SLE对照。感染后90天内SLE临床复发率感染组17.6%显著高于对照组5.5%(OR 3.67,95%CI 1.59–8.46,P=0.001)。两组抗dsDNA和补体水平变化无显著差异。
要点
- SARS-CoV2感染的SLE患者90天内临床复发率17.6%,显著高于未感染对照的5.5%(OR 3.67,P=0.001)。
- 感染组11/91(12.1%)出现严重表现,1例(1.1%)死亡,7例(7.7%)发生严重并发症。
- 感染前C3水平较低的SLE患者感染后更易出现临床复发(P=0.004)。
核心结论
- SARS-CoV2感染的SLE患者90天内临床复发显著多于匹配的未感染SLE对照(17.6% vs 5.5%,OR 3.67,95%CI 1.59–8.46,P=0.001)。
研究设计与样本
- 回顾性病例对照研究,从本院COVID-19登记库中识别2022年2月至11月期间确诊COVID-19且符合ACR/SLICC标准的SLE患者91例。
- 无SARS-CoV2感染的SLE对照按年龄、性别和感染时间以2:1比例随机匹配,共182例。
- 主要结局为COVID-19后90天内SLE临床复发(轻/中度或重度)。
主要发现
- 感染组年龄48.6(14.0)岁、女性95.6%;对照组年龄48.7(13.8)岁、女性95.6%。
- 感染组11/91(12.1%)出现严重表现,1例(1.1%)死亡,7例(7.7%)发生严重并发症。
- 感染后90天内14例(15.4%)发生轻/中度临床复发,2例(2.2%)发生重度复发。
- 感染组复发率17.6% vs 对照组5.5%(OR 3.67,95%CI 1.59–8.46,P=0.001)。
- 两组抗dsDNA和补体水平变化无显著差异;感染组中有临床复发者感染前C3值显著低于无复发者(P=0.004)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To study the effect of SARS-CoV2 infection on flares of systemic lupus erythematosus (SLE). METHODS: Patients who fulfilled the ACR/SLICC criteria for SLE and had documented COVID-19 between February and November 2022 were identified retrospectively from our hospital COVID-19 registry. SLE controls who did not have SARS-CoV2 infection were randomly matched for age, sex and the time of infection in a 2:1 ratio with those infected. The primary outcome of interest was clinical flare of SLE within 90 days of COVID-19. The rate of SLE flares (mild/moderate or severe) was compared between SARS-CoV2-infected SLE patients and controls. RESULTS: Ninety-one SLE patients with COVID-19 (age 48.6 (14.0) years; 95.6% women) and 182 SLE controls (age 48.7 (13.8) years; 95.6% women) were studied. Eleven of 91 (12.1%) SARS-CoV2-infected patients had serious manifestations. One (1.1%) patient died and 7 (7.7%) developed severe complications. Within 90 days of SARS-CoV2 infection, 14 (15.4%) patients developed mild/moderate clinical SLE flares and two (2.2%) patients had severe SLE flares. The incidence of SLE flares in SARS-CoV2-infected patients was significantly higher than in those without the infection (17.6% vs 5.5%; odds ratio 3.67 [95% CI: 1.59, 8.46]; P = 0.001). The changes in anti-dsDNA and complement levels, however, were not significantly different between the two groups. Among SARS-CoV2-infected SLE patients, those with clinical SLE flares had significantly lower C3 values (P = 0.004) before the infection than those without. CONCLUSION: Clinical flares within 90 days were significantly more common in SLE patients infected with SARS-CoV2 than matched non-infected SLE controls.
引用
- Mok CC, Cheung CCL, Chan KL, et al. Effect of SARS-CoV2 infection on disease flares in patients with systemic lupus erythematosus: a case-control study. Rheumatology (Oxford). 2024. PMID: 37947324. doi:10.1093/rheumatology/kead601
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。